Page 5 - EASL POSTGRADUATE COURSE
P. 5
EXTRAHEPATIC COMPLICATIONS OF LIVER FAT
56 WHY DOES LIVER FAT CONTRIBUTE TO CARDIO-METABOLIC OUTCOMES?
Hannele Yki-Jarvinen, Finland
59 NAFLD, PRE-ATHEROGENIC LESIONS AND CARDIOVASCULAR EVENTS
Sven M.A. Francque, Belgium
65 DOES STEATOSIS PLACE PATIENTS AT RISK FOR DIABETES DEVELOPMENT
AND PROGRESSION?
Naveed Sattar, The United Kingdom
67 CURRENT AND FUTURE INSULIN SENSITIZERS IN THE TREATMENT OF NASH
Vlad Ratziu, France
CARCINOGENESIS AND NAFLD
77 CARCINOGENESIS AND THE SPECTRUM OF HEPATIC TUMORS IN NASH
Augusto Villanueva, The United States
81 LIVER CANCER IN NAFLD:
MAGNITUDE OF THE PROBLEM
Jean-François Dufour, Switzerland
84 DO INFLAMMATION NETWORKS TRIGGER NASH AND DRIVE ITS PROGRESSION?
Herbert Tilg, Austria
87 IMPACT OF LIFESTYLE ON NASH (INCLUSIVE OF HCC)
Ingrid Hickman, Australia
PROGRESSION OF LIVER DISEASE IN NAFLD
93 WHO ARE THE NAFLD PATIENTS AT RISK OF DISEASE PROGRESSION?
Chris Day, The United Kingdom
99 NAFLD DIABETES AND ALCOHOL:
IS THERE A SAFE THRESHOLD?
Stefano Bellentani, Andrea Barchetti, Fabio Nascimbeni and Amedeo Lonardo,
The United Kingdom and Italy
103 THE COURSE OF CIRRHOTIC NASH:
HOW DIFFERENT IS IT FROM OTHER CIRRHOSES
Arun J. Sanyal, The United States
107 LIVER TRANSPLANTATION FOR NASH
Didier Samuel, France
The International Liver Congress™ 2015 • Vienna, Austria • April 22–23, 2015 5
56 WHY DOES LIVER FAT CONTRIBUTE TO CARDIO-METABOLIC OUTCOMES?
Hannele Yki-Jarvinen, Finland
59 NAFLD, PRE-ATHEROGENIC LESIONS AND CARDIOVASCULAR EVENTS
Sven M.A. Francque, Belgium
65 DOES STEATOSIS PLACE PATIENTS AT RISK FOR DIABETES DEVELOPMENT
AND PROGRESSION?
Naveed Sattar, The United Kingdom
67 CURRENT AND FUTURE INSULIN SENSITIZERS IN THE TREATMENT OF NASH
Vlad Ratziu, France
CARCINOGENESIS AND NAFLD
77 CARCINOGENESIS AND THE SPECTRUM OF HEPATIC TUMORS IN NASH
Augusto Villanueva, The United States
81 LIVER CANCER IN NAFLD:
MAGNITUDE OF THE PROBLEM
Jean-François Dufour, Switzerland
84 DO INFLAMMATION NETWORKS TRIGGER NASH AND DRIVE ITS PROGRESSION?
Herbert Tilg, Austria
87 IMPACT OF LIFESTYLE ON NASH (INCLUSIVE OF HCC)
Ingrid Hickman, Australia
PROGRESSION OF LIVER DISEASE IN NAFLD
93 WHO ARE THE NAFLD PATIENTS AT RISK OF DISEASE PROGRESSION?
Chris Day, The United Kingdom
99 NAFLD DIABETES AND ALCOHOL:
IS THERE A SAFE THRESHOLD?
Stefano Bellentani, Andrea Barchetti, Fabio Nascimbeni and Amedeo Lonardo,
The United Kingdom and Italy
103 THE COURSE OF CIRRHOTIC NASH:
HOW DIFFERENT IS IT FROM OTHER CIRRHOSES
Arun J. Sanyal, The United States
107 LIVER TRANSPLANTATION FOR NASH
Didier Samuel, France
The International Liver Congress™ 2015 • Vienna, Austria • April 22–23, 2015 5
